PROCYTE CORP. FILES REGISTRATION STATEMENT WITH S.E.C.
KIRKLAND, Wash., Dec. 7 /PRNewswire/ -- ProCyte Corp. (NASDAQ-NMS: PRCY) announced today that it has filed an S-3 registration statement with the Securities and Exchange Commission containing a prospectus for a proposed new issue of two and one-half million shares of the company's common stock. The offering will be co-managed by Wertheim Schroder & Co. and Dain Bosworth Inc. ProCyte Corp. is a pharmaceutical company engaged in the development of a proprietary class of copper therapeutic compounds for topical and systemic application to human health care needs. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor any offers to buy be accepted prior to the time the registration statement becomes effective. This announcement does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A copy of the written preliminary prospectus may be obtained from Wertheim Schroder & Co., 212-492-6900. -0- 12/7/93 /CONTACT: Karen L. Hedine, vice president, or Joseph Ashley, president and chief executive officer, of ProCyte, 206-820-4548/ (PRCY)
CO: ProCyte Corp. ST: Washington IN: MTC SU:
RB-JH -- SE010 -- 1339 12/07/93 14:03 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 7, 1993|
|Previous Article:||OMEGA FINANCIAL ANNOUNCES INCREASED DIVIDEND|
|Next Article:||KIMCO HOTEL & RESTAURANT MANAGEMENT CO. ASSUMES MANAGEMENT OF LANDMARK SIR FRANCIS DRAKE HOTEL|